At Tango, we are committed to patient health, safety and well-being. The patient is part of our process from discovery through to development, and we focus our research and development on areas where we can make a difference in the lives of patients with few or no effective therapeutic options.
We are developing and testing oncology medicines to expand the treatment options for those living with cancer.
MTAP-deleted cancers
Evaluating safety, tolerability, and preliminary antitumor activity of TNG456 monotherapy and in combination with abemaciclib in patients with solid tumors with MTAP loss.
MTAP-deleted and RAS-mutant cancers
Evaluating safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral vopimetostat in combination with daraxonrasib or zoldonrasib (Revolution Medicines) in patients with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic non-small cell lung cancer (NSCLC) and oral vopimetostat in combination with chemotherapy in patients with untreated locally advanced or metastatic pancreatic cancer with MTAP loss.
STK11 mutant/KRAS wild type cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260in combination with pembrolizumab, in patients with locally advanced or metastatic solid tumors with an STK11 loss-of-function mutation and KRAS wild type.
MTAP-deleted cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of vopimetostat in patients with solid tumors with MTAP deletions.
MTAP-deleted cancers
Evaluating safety, pharmacokinetics, pharmocodynamics, and preliminary clinical activity of TNG908 in patients with MTAP-deleted cancers.
Compassionate Use
We believe that the best way for patients to access investigational medicines is through a clinical trial. Our clinical trials are listed at ClinicalTrials.gov and include eligibility criteria. If you are interested in learning whether enrollment in a clinical trial is an option for you or someone you know, please consult with the treating physician, who can contact us as needed with questions.
When enrollment in a clinical trial is not an option, and all currently available treatment options have been tried, an investigational medicine may be provided before it is commercially available under programs called Expanded Access or Compassionate Use, which are regulated by the US Food and Drug Administration. Investigational medicines provided by Tango under these circumstances will always be given in accordance with applicable laws and regulations.
Currently, our program is restricting enrollment to patients who are responding to or benefitting from treatment on closing Tango studies, who would otherwise lose access to their current treatment at time of study closure.
We recognize the urgency faced by patients with limited treatment options. We hope to expand our access, at a time in which doing so will not compromise ongoing clinical trials, regulatory submissions, or our ability to develop therapies for broader patient populations. We will regularly reassess our policy as clinical development progresses and regulatory landscapes evolve.
All Compassionate Use requests should come from a treating physician (compassionateuse@tangotx.com). We answer all such requests as soon as possible (but in any event, within five business days). Physicians who administer Tango investigational medicines through a Compassionate Use program must comply with all applicable laws and regulations and contractual conditions, including those relating to safety reporting.
Tango Therapeutics
201 Brookline Ave, Suite 901
Boston, MA 02215
Tel: +1-857-320-4900